Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-Phenylbutyrate for ABCB11-Mutated Hereditary Cholestasis
NCT04531878Phase 3Withdrawn
- Sponsor
- Children's Hospital of Fudan University
- Start
- Feb 2023
- Primary completion
- Feb 2023
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of sodium phenylbutyrate in progressive familial intrahepatic cholestasis type 2 (PFIC2), sponsored by Children's Hospital of Fudan University. Planned start Feb 2023; status: withdrawn.
02
Drugs
sodium phenylbutyrate
03
Conditions
progressive familial intrahepatic cholestasis type 2 (PFIC2)
Beyond the preview
Go deeper on NCT04531878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04531878.